Cancer Drugs Dominate Approval Landscape

In a dramatic upsurge since the 1980s, cancer drugs now account for more than one-fourth of all new drug approvals in the United States since 2010, up from 4% a […]

Sponsors Want to Hear from Sites—With Evidence

Sites, especially smaller and newer ones, don’t like to challenge sponsors during a clinical trial, and that’s understandable, says Melissa Holbrook, MSN, NP, vice president for operations with Velocity Clinical […]